Wave 80 Biosciences

Molecular diagnostic company Wave 80 Biosciences has received Phase I Small Business Innovation Research funding from the National Institutes of Health to develop rapid sample prep to support chlamydia testing in low-resource settings.

Bay Area molecular diagnostics shop Wave 80 Biosciences is gearing up to evaluate its first product — a semi-quantitative HIV viral load assay that runs on the company's cartridge-based, near-patient, sample-to-answer testing system — in full-scale clinical trials by the end of t

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.